8月8日，奥洛兹美医疗盘中上涨16.87%，报100.23美元/股，成交额3.79亿美元。
消息面上，公司发布第二季度财报，业绩全面大幅超出市场预期。Q2调整后每股收益2.28美元，远超分析师一致预期的1.84美元，同比增长48%；营收4.81亿美元，超预期约19%，同比增长47.7%。公司同时大幅上调全年指引，预计调整后每股收益8.65至9.00美元，营收指引上调至18.35亿至19.1亿美元，均显著高于市场预期。强劲增长主要受ENHANZE技术平台特许权使用费持续放量驱动。
此外，多家投行跟进上调评级及目标价：Leerink Partners将评级上调至"跑赢大盘"，目标价从83美元升至110美元；Morgan Stanley将目标价从93美元上调至105美元，维持"增持"评级。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.